• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1

tetano

Editor, Senior Moderator
Biopolymers. 2013 Jan;99(1):10-21. doi: 10.1002/bip.22130.
Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1.
Tolentino-Lopez L, Segura-Cabrera A, Reyes-Loyola P, Zimic M, Quiliano M, Briz V, Mu?oz-Fern?ndez A, Rodr?guez-P?rez M, Ilizaliturri-Flores I, Correa-Basurto J.
Source

Laboratorio de Modelado Molecular y Bioinform?tica, Secci?n de Estudios de Posgrado e Investigaci?n, Escuela Superior de Medicina, Instituto Polit?cnico Nacional, Plan de San Luis y D?az Mir?n, M?xico City 11340, M?xico.
Abstract

The recent occurrence of 2009 influenza A (H1N1) pandemic as well as others has raised concern of a far more dangerous outcome should this virus becomes resistant to current drug therapies. The number of clinical cases that are resistant to oseltamivir (Tamiflu?) is larger than the limited number of neuraminidase (NA) mutations (H275Y, N295S, and I223R) that have been identified at the active site and that are associated to oseltamivir resistance. In this study, we have performed a comparative analysis between a set of NAs that have the most representative mutations located outside the active site. The recently crystallized NA-oseltamivir complex (PDB ID: 3NSS) was used as a wild-type structure. After selecting the target NA sequences, their three-dimensional (3D) structure was built using 3NSS as a template by homology modeling. The 3D NA models were refined by molecular dynamics (MD) simulations. The refined models were used to perform a docking study, using oseltamivir as a ligand. Furthermore, the docking results were refined by free-energy analysis using the MM-PBSA method. The analysis of the MD simulation results showed that the NA models reached convergence during the first 10 ns. Visual inspection and structural measures showed that the mutated NA active sites show structural variations. The docking and MM-PBSA results from the complexes showed different binding modes and free energy values. These results suggest that distant mutations located outside the active site of NA affect its structure and could be considered to be a new source of resistance to oseltamivir, which agrees with reports in the clinical literature. ? 2012 Wiley Periodicals, Inc.

Copyright ? 2012 Wiley Periodicals, Inc.

PMID:
23097226
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/23097226
 
Back
Top Bottom